Published in Medical Devices and Surgical Technology Week, October 24th, 2004
"This is a major milestone for Artimplant. The North American market represents more than 50% of the world market. Hand surgeons in the U.S. are waiting to treat patients with our Spacer. This product has considerable potential, which was clearly shown at the American Society for the Surgery of the Hand meeting," said Tord Lendau, CEO of Artimplant.
"Another 90 days was added to the FDA review process, because further information was requested. Consequently, a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Devices and Surgical Technology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.